BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 28179525)

  • 41. Interferon-γ-inducible protein 16 (IFI16) is required for the maintenance of Epstein-Barr virus latency.
    Pisano G; Roy A; Ahmed Ansari M; Kumar B; Chikoti L; Chandran B
    Virol J; 2017 Nov; 14(1):221. PubMed ID: 29132393
    [TBL] [Abstract][Full Text] [Related]  

  • 42. EBV Infection and Glucose Metabolism in Nasopharyngeal Carcinoma.
    Zhang J; Jia L; Tsang CM; Tsao SW
    Adv Exp Med Biol; 2017; 1018():75-90. PubMed ID: 29052133
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Protein kinase C-independent activation of the Epstein-Barr virus lytic cycle.
    Gradoville L; Kwa D; El-Guindy A; Miller G
    J Virol; 2002 Jun; 76(11):5612-26. PubMed ID: 11991990
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Methylation-dependent binding of the epstein-barr virus BZLF1 protein to viral promoters.
    Dickerson SJ; Xing Y; Robinson AR; Seaman WT; Gruffat H; Kenney SC
    PLoS Pathog; 2009 Mar; 5(3):e1000356. PubMed ID: 19325883
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The cellular ataxia telangiectasia-mutated kinase promotes epstein-barr virus lytic reactivation in response to multiple different types of lytic reactivation-inducing stimuli.
    Hagemeier SR; Barlow EA; Meng Q; Kenney SC
    J Virol; 2012 Dec; 86(24):13360-70. PubMed ID: 23015717
    [TBL] [Abstract][Full Text] [Related]  

  • 46. IRF4 promotes Epstein-Barr virus activation in Burkitt's lymphoma cells.
    Gao Y; Wang L; Lei Z; Li J; Forrest JC; Liang X
    J Gen Virol; 2019 May; 100(5):851-862. PubMed ID: 30907723
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sumoylation of the Epstein-Barr virus BZLF1 protein inhibits its transcriptional activity and is regulated by the virus-encoded protein kinase.
    Hagemeier SR; Dickerson SJ; Meng Q; Yu X; Mertz JE; Kenney SC
    J Virol; 2010 May; 84(9):4383-94. PubMed ID: 20181712
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The BRRF1 early gene of Epstein-Barr virus encodes a transcription factor that enhances induction of lytic infection by BRLF1.
    Hong GK; Delecluse HJ; Gruffat H; Morrison TE; Feng WH; Sergeant A; Kenney SC
    J Virol; 2004 May; 78(10):4983-92. PubMed ID: 15113878
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A positive autoregulatory loop of LMP1 expression and STAT activation in epithelial cells latently infected with Epstein-Barr virus.
    Chen H; Hutt-Fletcher L; Cao L; Hayward SD
    J Virol; 2003 Apr; 77(7):4139-48. PubMed ID: 12634372
    [TBL] [Abstract][Full Text] [Related]  

  • 50. De novo protein synthesis is required for lytic cycle reactivation of Epstein-Barr virus, but not Kaposi's sarcoma-associated herpesvirus, in response to histone deacetylase inhibitors and protein kinase C agonists.
    Ye J; Gradoville L; Daigle D; Miller G
    J Virol; 2007 Sep; 81(17):9279-91. PubMed ID: 17596302
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rapamycin enhances lytic replication of Epstein-Barr virus in gastric carcinoma cells by increasing the transcriptional activities of immediate-early lytic promoters.
    Wang M; Wu W; Zhang Y; Yao G; Gu B
    Virus Res; 2018 Jan; 244():173-180. PubMed ID: 29169830
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Regulation of DNA Damage Signaling and Cell Death Responses by Epstein-Barr Virus Latent Membrane Protein 1 (LMP1) and LMP2A in Nasopharyngeal Carcinoma Cells.
    Wasil LR; Wei L; Chang C; Lan L; Shair KH
    J Virol; 2015 Aug; 89(15):7612-24. PubMed ID: 25972552
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Epstein-Barr virus immediate-early proteins BZLF1 and BRLF1 activate the ATF2 transcription factor by increasing the levels of phosphorylated p38 and c-Jun N-terminal kinases.
    Adamson AL; Darr D; Holley-Guthrie E; Johnson RA; Mauser A; Swenson J; Kenney S
    J Virol; 2000 Feb; 74(3):1224-33. PubMed ID: 10627532
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Luteolin inhibits Epstein-Barr virus lytic reactivation by repressing the promoter activities of immediate-early genes.
    Wu CC; Fang CY; Hsu HY; Chen YJ; Chou SP; Huang SY; Cheng YJ; Lin SF; Chang Y; Tsai CH; Chen JY
    Antiviral Res; 2016 Aug; 132():99-110. PubMed ID: 27185626
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of targeting sumoylation processes during latent and induced Epstein-Barr virus infections using the small molecule inhibitor ML-792.
    Garcia P; Harrod A; Jha S; Jenkins J; Barnhill A; Lee H; Thompson M; Williams JP; Barefield J; Mckinnon A; Suarez P; Shah A; Lowrey AJ; Bentz GL
    Antiviral Res; 2021 Apr; 188():105038. PubMed ID: 33577806
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Air-Liquid Interface Method To Study Epstein-Barr Virus Pathogenesis in Nasopharyngeal Epithelial Cells.
    Caves EA; Cook SA; Lee N; Stoltz D; Watkins S; Shair KHY
    mSphere; 2018 Jul; 3(4):. PubMed ID: 30021875
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Interferon regulatory factor 7 regulates expression of Epstein-Barr virus latent membrane protein 1: a regulatory circuit.
    Ning S; Hahn AM; Huye LE; Pagano JS
    J Virol; 2003 Sep; 77(17):9359-68. PubMed ID: 12915551
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tumor Suppressor p53 Stimulates the Expression of Epstein-Barr Virus Latent Membrane Protein 1.
    Wang Q; Lingel A; Geiser V; Kwapnoski Z; Zhang L
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28794023
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An Epstein-Barr Virus (EBV) mutant with enhanced BZLF1 expression causes lymphomas with abortive lytic EBV infection in a humanized mouse model.
    Ma SD; Yu X; Mertz JE; Gumperz JE; Reinheim E; Zhou Y; Tang W; Burlingham WJ; Gulley ML; Kenney SC
    J Virol; 2012 Aug; 86(15):7976-87. PubMed ID: 22623780
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Epstein-Barr Virus Lytic Reactivation Activates B Cells Polyclonally and Induces Activation-Induced Cytidine Deaminase Expression: A Mechanism Underlying Autoimmunity and Its Contribution to Graves' Disease.
    Nagata K; Kumata K; Nakayama Y; Satoh Y; Sugihara H; Hara S; Matsushita M; Kuwamoto S; Kato M; Murakami I; Hayashi K
    Viral Immunol; 2017 Apr; 30(3):240-249. PubMed ID: 28333576
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.